<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806035</url>
  </required_header>
  <id_info>
    <org_study_id>TG-1801-102</org_study_id>
    <nct_id>NCT04806035</nct_id>
  </id_info>
  <brief_title>Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TG Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TG Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects&#xD;
      with B-Cell Lymphoma or Chronic Lymphocytic Leukemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Phase Ib open-label, multi-center, dose-finding study. Once a single-agent dose level is declared safe, the study will evaluate sequentially higher doses of TG-1801 in combination with ublituximab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the overall response rate (ORR) of TG-1801 alone and in combination with ublituximab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>CLL</condition>
  <condition>SLL</condition>
  <condition>Richter's Transformation</condition>
  <condition>Indolent Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Aggressive Lymphoma</condition>
  <condition>DLBCL</condition>
  <condition>Mediastinal Large B-cell Lymphoma</condition>
  <condition>MCL</condition>
  <arm_group>
    <arm_group_label>TG-1801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG-1801 Single Agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TG-1801 + Ublituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG-1801 in combination with ublituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TG-1801</intervention_name>
    <description>It is a bispecific, first-in-class, CD47 and CD19 antibody</description>
    <arm_group_label>TG-1801</arm_group_label>
    <arm_group_label>TG-1801 + Ublituximab</arm_group_label>
    <other_name>NI-1701</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ublituximab</intervention_name>
    <description>recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks</description>
    <arm_group_label>TG-1801 + Ublituximab</arm_group_label>
    <other_name>TG-1101</other_name>
    <other_name>LFB-R603</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  B-cell non-Hodgkin lymphoma (NHL) including RT and transformed FL, that warrants&#xD;
             systemic therapy&#xD;
&#xD;
          -  Chronic Lymphocytic Leukemia (CLL), that warrants systemic therapy as defined by iwCLL&#xD;
             (Hallek 2018)&#xD;
&#xD;
          -  Treatment Status:&#xD;
&#xD;
               1. NHL subjects: relapsed to or refractory after at least two prior standard&#xD;
                  systemic therapies (excluding antibiotics)&#xD;
&#xD;
               2. RT subjects: must have relapsed after or be refractory to at least two prior line&#xD;
                  of therapy for CLL/SLL or RT&#xD;
&#xD;
               3. CLL subjects: relapsed to or refractory after at least two prior standard&#xD;
                  therapies&#xD;
&#xD;
          -  Measurable disease defined as:&#xD;
&#xD;
               1. NHL (including SLL): at least 1 measurable disease lesion &gt; 1.5 cm&#xD;
&#xD;
               2. CLL: at least 1 measurable disease lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with any agent blocking the CD47/SIRPÎ± pathway or any previous CD19&#xD;
             targeting therapy,&#xD;
&#xD;
          -  Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy,&#xD;
             immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)&#xD;
             or any investigational drug within 21 days of Day 1 of Cycle 1&#xD;
&#xD;
          -  Prior autologous SCT within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TG Therapeutics Clinical Support Team</last_name>
    <phone>1-877-555-8489</phone>
    <email>clinicalsupport@tgtxinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

